[
    [
        {
            "time": "2018-03-15",
            "original_text": "Array BioPharma Gains on Colorectal Cancer Study Success",
            "features": {
                "keywords": [
                    "Array",
                    "BioPharma",
                    "Colorectal",
                    "Cancer",
                    "Study",
                    "Success"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biopharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Array BioPharma Gains on Colorectal Cancer Study Success",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "3 Tech Stocks for Growth Investors to Buy Right Now",
            "features": {
                "keywords": [
                    "Tech",
                    "Stocks",
                    "Growth",
                    "Investors",
                    "Buy"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Tech Stocks for Growth Investors to Buy Right Now",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-06-17",
            "original_text": "Eli Lilly says lower-priced insulin is now available",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "lower-priced",
                    "insulin",
                    "available"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly says lower-priced insulin is now available",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-29",
            "original_text": "Merck to Buy Private Cancer Drugmaker Peloton Therapeutics",
            "features": {
                "keywords": [
                    "Merck",
                    "Buy",
                    "Private",
                    "Cancer",
                    "Drugmaker",
                    "Peloton",
                    "Therapeutics"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biopharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck to Buy Private Cancer Drugmaker Peloton Therapeutics",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-05",
            "original_text": "Lilly's Crohn's Disease Candidate Meets Phase II Study Goals",
            "features": {
                "keywords": [
                    "Lilly",
                    "Crohn's",
                    "Disease",
                    "Candidate",
                    "Phase",
                    "II",
                    "Study",
                    "Goals"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Crohn's Disease Candidate Meets Phase II Study Goals",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-10",
            "original_text": "Should We Worry About Eli Lilly and Company's (NYSE:LLY) P/E Ratio?",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "P/E",
                    "Ratio",
                    "Worry"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Should We Worry About Eli Lilly and Company's (NYSE:LLY) P/E Ratio?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-20",
            "original_text": "Eli Lilly's Insulin Lispro Injection available at half the list price of Humalog",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Insulin",
                    "Lispro",
                    "Injection",
                    "half",
                    "price",
                    "Humalog"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly's Insulin Lispro Injection available at half the list price of Humalog",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-01",
            "original_text": "Lilly selling half-price version of popular Humalog insulin",
            "features": {
                "keywords": [
                    "Lilly",
                    "selling",
                    "half-price",
                    "version",
                    "Humalog",
                    "insulin"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly selling half-price version of popular Humalog insulin",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-15",
            "original_text": "Lilly's Lower-Priced Insulin Now Available",
            "features": {
                "keywords": [
                    "Lilly",
                    "Lower-Priced",
                    "Insulin",
                    "Available"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Lower-Priced Insulin Now Available",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]